Drug Profile
Research programme: cancer therapeutics - Sprint Bioscience/Karolinska Institute
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Sprint Bioscience
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Acute-myeloid-leukaemia in Sweden
- 29 Jun 2016 Early research in Acute myeloid leukaemia in Sweden (unspecified route) prior to June 2016
- 29 Jun 2016 Sprint Bioscience collaborates with the Karolinska Institute for the development of therapies for Acute myeloid leukaemia